Beyond BRCA: Emerging Germline Targets for PARP Inhibitors

Could other mutations predict PARP benefit? Dr. Robson highlights PALB2 as a promising candidate, while distinguishing why CHEK2 and ATM carriers likely won’t benefit. A look at the next frontier of germline-directed therapy.